Effects of switching from MiniMed™ 770G to 780G on continuous glucose monitoring metrics and DTR-QOL scores: An observational study of Japanese people with type 1 diabetes mellitus.
We sought to compare the MiniMed™ 770G to the 780G insulin pump for glycemic control and quality of life in Japanese adults with T1D over a one-year period.
Thirty-six adults with T1D who switched from the MiniMed™ 770G to the 780G system were analyzed over 48 weeks using continuous glucose monitoring data, retrospectively. The percentages of time within the target glucose range (70-180 mg/dL), time above 180 mg/dL, and time below 70 mg/dL were compared before and after switching. Quality of life (QOL) scores were also evaluated in 39 patients using a validated questionnaire, prospectively.
After switching to the MiniMed™ 780G, the time within the target glucose range significantly increased from 71.6 ± 12.4% to 76.1 ± 10.2% (P < 0.01), while the time above 180 mg/dL decreased from 25.2 ± 13.4% to 21.0 ± 11.0% (P < 0.01). The time below 70 mg/dL did not differ significantly overall, but nocturnal hypoglycemia decreased from 4.9% to 2.7% (P = 0.02). Glycated hemoglobin improved from 7.2 ± 0.8% to 7.0 ± 0.7% (P < 0.01). Although the total QOL score did not change significantly, the subscales reflecting anxiety and treatment satisfaction improved significantly.
Switching from the MiniMed™ 770G to the 780G system in Japanese adults with T1D improved both glycemic control and treatment-related QOL, supporting the clinical usefulness of the 780G in real-world clinical practice. This study provides the first one-year real-world evidence of MiniMed™ 780G use in Japan.
Thirty-six adults with T1D who switched from the MiniMed™ 770G to the 780G system were analyzed over 48 weeks using continuous glucose monitoring data, retrospectively. The percentages of time within the target glucose range (70-180 mg/dL), time above 180 mg/dL, and time below 70 mg/dL were compared before and after switching. Quality of life (QOL) scores were also evaluated in 39 patients using a validated questionnaire, prospectively.
After switching to the MiniMed™ 780G, the time within the target glucose range significantly increased from 71.6 ± 12.4% to 76.1 ± 10.2% (P < 0.01), while the time above 180 mg/dL decreased from 25.2 ± 13.4% to 21.0 ± 11.0% (P < 0.01). The time below 70 mg/dL did not differ significantly overall, but nocturnal hypoglycemia decreased from 4.9% to 2.7% (P = 0.02). Glycated hemoglobin improved from 7.2 ± 0.8% to 7.0 ± 0.7% (P < 0.01). Although the total QOL score did not change significantly, the subscales reflecting anxiety and treatment satisfaction improved significantly.
Switching from the MiniMed™ 770G to the 780G system in Japanese adults with T1D improved both glycemic control and treatment-related QOL, supporting the clinical usefulness of the 780G in real-world clinical practice. This study provides the first one-year real-world evidence of MiniMed™ 780G use in Japan.
Authors
Takagi Takagi, Sato Sato, Ayame Ayame, Fujikawa Fujikawa, Mori Mori, Yasuda Yasuda, Ozaki Ozaki, Nagashima Nagashima, Koshibu Koshibu, Nishida Nishida, Ikeda Ikeda, Watada Watada
View on Pubmed